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Abstract
Peripartum cardiomyopathy (PPCM) is a rare form of dilated
cardiomyopathy that occurs in previously healthy women in the last
month of pregnancy and up to several months after delivery. The
incidence of PPCM is low, but its morbidity and mortality rate are high,
with a substantial risk of poor outcome of the pregnancy. Patients who
have recovered from PPCM run a high risk of reoccurrence in subsequent
pregnancies. In this case report we present a 32-year old female patient
who developed acute heart failure (HF) associated with significantly
reduced systolic function due to PPCM soon after a delivery of triplets.
Treatment was immediately initiated in the intensive coronary unit with
oxygen-therapy, loop diuretics, aldosterone blockers, beta blockers,
angiotensin-converting enzyme (ACE) inhibitors and bromocriptine.
During the follow up period, a year and a half after delivery, a complete
recovery of systolic function was observed with no residual symptoms.
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Introduction
Peripartum cardiomyopathy (PPCM) is a rare form of cardiomyopathy
characterized by the development of heart failure (HF) due to left
ventricular systolic dysfunction. Since 1997, four diagnostic criteria,
proposed by the American National Heart, Lung, and Blood Institute and
the Office of Rare Diseases Research, are used to diagnose this condition.
They are: (a) the development of HF in the last month of pregnancy or
within five months of delivery; (b) the absence of a determinable etiology
for HF; (c) the absence of demonstrable heart disease before the last
month of pregnancy; (d) left ventricular systolic dysfunction defined by a
left ventricular ejection fraction (LVEF) < 45%, fractional shortening
<30%, or both. (1,2) The incidence of PPCM ranges from 1:300 to
1:15,000 live births. The published mortality rates range from 25 to 50%.
(3) Etiology is unclear but it may be connected to hemodynamic and
hormonal changes in pregnancy or cytokine dysfunction. (4) There are a
number of factors that are associated with PPCM such as: preeclampsia,
multiparity, advanced maternal age, multiple pregnancy, cocaine abuse,
selenium deficiency and prolonged oral tocolytic therapy with beta
adrenergic agonists. The treatment is based on the administration of
standard drug therapy for acute and chronic HF that includes the use of
diuretics, intravenous and oral vasodilatators, intravenous inotropes,
angiotensin-converting enzyme (ACE) inhibitors or angiotensin II
receptor blockers, beta-blockers, spironolactone, and digoxin. (5,6)
Case report
In this case report we present a 32-year old female patient who developed
PPCM after delivering triplets. She was admitted to the gynecology and
obstetrics clinic in the 32nd gestational week.
Her past medical history was unremarkable. No cardiovascular disease
was noticed. Physical status was within normal limits. Up to the 30th
week of gestation the pregnancy was uneventful. At that time shortness of
breath was noticed, but this was attributed to advanced/ triplet
pregnancy. In the 35th gestational week elective cesarean section was
performed. Three healthy babies were delivered. The early postoperative
period was unremarkable. Post-delivery, arterial hypertension was
discovered and treated with urapidil and nifedipine. Five days after
delivery, the patient reported shortness of breath. Oxygen saturation was
reduced to 92%. Chest examination revealed bilateral crackles. A gallop
rhythm with a holosystolic murmur (intensity 4/6, loudest heard at the
apex) was noticed. Chest X-ray showed pulmonary interstitial edema, an
increase in the cardiac silhouette and bilateral pleural effusion.
Echocardiography showed a dilated left ventricle (to 62 mm), reduced
systolic function of the left ventricle (LVEF-35% by Simpson
measurement), an enlarged left atrium (dimensions 64×66 mm), massive
mitral regurgitation, good contractility of the right ventricle (tricuspid
annular plane systolic excursion-TAPSE 26 mm) and medium tricuspid
regurgitation with pulmonary hypertension (pulmonary artery systolic
pressure – PASP 75 mmHg). MSCT pulmonary angiography showed no
thrombi in the pulmonary circulation. Initial N-terminal proBrain
Natriuretic Peptide (NTproBNP) level was 15 316 pg/ml (normal values
<125 pg/ml). The patient was transferred to the intensive coronary unit
where she was treated with oxygen-therapy, loop diuretics, aldosterone
blockers, beta blockers, ACE inhibitors, bromocriptine and other
supportive therapy.
After prolonged hospitalization, for more than a month,
echocardiography showed improvement in systolic function and a normal
sized left ventricle (53 mm), with generally reduced contractility
(LVEF~45%) (figure 1). A very mild mitral regurgitation was present and
the pressure gradient over the tricuspid valve was 20 mmHg. NTproBNP
level was now 102 pg/ml, respectively. On discharge the patient was
clinically stable, without dyspnea. She was offered bisoprolol with
minimal doses of furosemide, spironolactone and valsartan. Six months
later, only bisoprolol was continued.
Two years after delivery the patient presented asymptomatic with a
normal physical status and no echocardiographic abnormalities (figure
2).
Discussion
This case report presents a normal pregnancy with PPCM that developed
soon after delivery. By rapidly diagnosing the condition, thanks to well
established criteria, and promptly initiating treatment, a good short and
long term outcome was achieved .
An unremarkable history, along with symptoms of congestive heart
failure, are usually present, which should lead the clinician to think of
PPCM. Echocardiography, as a goal standard in cardiac imaging, and
elevated natriuretic peptides can confirm the diagnosis. In our case we
emphasize the triplet pregnancy as a predisposing risk factor for PPCM.
Treatment is focused on reduction of preload and afterload and
improving cardiac contractility. Diuretics, beta blockers and ACE
inhibitors are the main choice of treatment. (5,6) Some reports show
beneficial effects of human immunoglobulins. (7) We also used
bromocriptine because of its potential benefit on PCCM. (8)
Although rare, PPCM requires awareness and care, due to its high
mortality and morbidity. A pregnancy aggravated by a dilated left
ventricle can lead to unwanted thromboembolic events, rapid HF or
sudden death. (9,10) Patients who have recovered from PPCM run a high
risk for the disease in subsequent pregnancies. Preterm delivery and
maternal mortality remain the highest problem. Therefore, these patients
should be advised to avoid further pregnancies. If the patient insists on a
new pregnancy, a thorough clinical follow-up every six months is needed
until systolic function improves to at least 50%. At that point a new
pregnancy could be planned with proper cautions in place. Taking into
account that in twin pregnancies cardiac output is 20 percent higher than
in women carrying singletons, and it peaks at 30 weeks of gestation, we
can presume that in this case PPCM was mostly caused by the triplet
pregnancy. (4) In our patient, a future singleton pregnancy could be
considered, given the patient’s full recovery and the fact that the previous
pregnancy was a triplet. If cardiac function does not fully recover, future
pregnancies should be avoided.
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Figure 1. Parasternal long-axis echocardiogram view (PLAX view) –
reduced systolic function of a dilated left ventricle (15 days after
hospitalization).
Figure 2. Parasternal long-axis echocardiogram view (PLAX view) –
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